Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International Raises $1.4M

NEW YORK (GenomeWeb) – Proteomics International Laboratories said today it has raised $1.4 million through the placement of 6 million shares of stock at $.24 per share.

The company also announced a share purchase plan for an additional 2 million shares, intending to raise an additional $480,000 at $.24 per share from existing shareholders.

Proteomic International said it will use $500,000 to commercialize its PromarkerD test, a proteomic test for diagnosing and predicting risk of diabetic kidney disease, and another $500,000 to launch an analytical testing services business aimed at the clinical trials market. Both actions will continue to push the company towards cash-flow positive operations, Proteomics International said in a statement.

The balance of the proceeds will be used to fund day-to-day operations.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.